4//SEC Filing
DeGolyer Donald W 4
Accession 0000899243-22-031344
CIK 0001537917other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 6:00 PM ET
Size
17.7 KB
Accession
0000899243-22-031344
Insider Transaction Report
Form 4
DeGolyer Donald W
Director
Transactions
- Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−100,000→ 0 totalExercise: $2.90Exp: 2028-05-24→ Common Stock (100,000 underlying) - Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−50,000→ 0 totalExercise: $1.18Exp: 2029-08-22→ Common Stock (50,000 underlying) - Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−50,000→ 0 totalExercise: $2.33Exp: 2028-08-26→ Common Stock (50,000 underlying) - Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−88,000→ 0 totalExercise: $1.10Exp: 2031-08-23→ Common Stock (88,000 underlying) - Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−65,000→ 0 totalExercise: $1.22Exp: 2030-08-19→ Common Stock (65,000 underlying) - Disposition to Issuer
Director Stock Option - Option to buy
2022-09-16−88,000→ 0 totalExercise: $0.31Exp: 2032-08-23→ Common Stock (88,000 underlying)
Footnotes (6)
- [F1]This option was fully vested and assumed by Syros Pharmaceuticals, Inc. ("Syros") in its merger with the issuer and replaced with an option to purchase 4,382 shares of Syros common stock for $66.18 per share, after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split").
- [F2]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $53.17 per share, after giving effect to the Reverse Split.
- [F3]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $26.93 per share, after giving effect to the Reverse Split.
- [F4]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,848 shares of Syros common stock for $27.84 per share, after giving effect to the Reverse Split.
- [F5]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $25.10 per share, after giving effect to the Reverse Split.
- [F6]This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 3,856 shares of Syros common stock for $7.07 per share, after giving effect to the Reverse Split.
Documents
Issuer
TYME TECHNOLOGIES, INC.
CIK 0001537917
Entity typeother
Related Parties
1- filerCIK 0001583098
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 6:00 PM ET
- Size
- 17.7 KB